PerkinElmer and Verinata Health Announce Collaboration to Expand Access to Non-Invasive Prenatal Test for Down Syndrome and

  PerkinElmer and Verinata Health Announce Collaboration to Expand Access to
  Non-Invasive Prenatal Test for Down Syndrome and Other Chromosomal
  Abnormalities

  Global Maternal and Fetal Health Leader and NIPT Innovator Join To Provide
           Comprehensive Prenatal Solutions for Doctors and Parents

Business Wire

WALTHAM, Mass. & REDWOOD CITY, Calif. -- January 9, 2013

PerkinElmer, Inc. (NYSE: PKI) and Verinata Health, Inc., today announced a
strategic agreement for expanding access to Verinata’s verifi^® test, the most
comprehensive non-invasive prenatal test (NIPT) currently available for
high-risk pregnancies. The verifi^® test, which is performed at Verinata’s
CLIA-certified, California laboratory, uses a single maternal blood draw as
early as 10 weeks of pregnancy to detect multiple fetal chromosomal
aneuploidies. Chromosomal aneuploidy is an abnormal number of chromosomes.

Under the terms of the collaboration agreement, PerkinElmer will serve as an
exclusive Verinata Health commercial partner in the joint sales and marketing
of the verifi^® test in the United States. The collaboration consolidates and
streamlines delivery of prenatal testing options due to the combination of
PerkinElmer’s extensive prenatal testing menu with Verinata’s proprietary
technologies for the early, non-invasive identification of specific fetal
chromosomal aneuploidies.

“PerkinElmer has a strong history and commitment to bring innovative offerings
that are dedicated to maternal and fetal health, to physicians and patients.
Integrating Verinata’s non-invasive prenatal test with PerkinElmer’s existing
solutions ensures that physicians and patients have early access to the most
advanced testing solutions to help protect the health of mothers and babies
and we look forward to working with Illumina,” said Robert Friel, Chairman and
Chief Executive Officer of PerkinElmer.

In December 2012, the American College of Obstetricians and Gynecologists
(ACOG) and the Society for Maternal-Fetal Medicine issued a joint Committee
Opinion stating that NIPT is one option that can be used as a primary or
secondary screening test for pregnancies with an increased risk for
aneuploidy. This includes women who will be 35 years of age or older at
delivery, women with a prior personal or family history of chromosome
abnormalities, pregnancies that have received abnormal biochemical screening
results, and pregnancies showing ultrasound abnormalities. Further asserting
the importance of screening, this new opinion follows ACOG’s Practice
Guidelines in 2007 which recommended that the option of screening and invasive
diagnostic testing for aneuploidy be offered to all pregnant women, regardless
of age.

Highly accurate biochemical screening results can be received as early as 11
weeks gestation, through the current PerkinElmer NTD Labs offering for Down
syndrome and other chromosomal abnormalities. The verifi^® prenatal test can
be considered for women who have received high risk first trimester screening
results at PerkinElmer’s NTD Labs early in the first trimester of pregnancy.

“Given our growing success with the verifi^® prenatal test, we are excited
that PerkinElmer has chosen our advanced technology as their NIPT offering,”
said Jeff Bird, M.D., Chief Executive Officer and Executive Chairman at
Verinata. “Collaborating with PerkinElmer provides a great opportunity to not
only offer expectant mothers greater access to complete high quality screening
and diagnostic tests, but to also extend the verifi prenatal test to the over
160 million people who are currently part of PerkinElmer’s contracted managed
care network.”

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, but not
limited to, statements relating to estimates and projections of future
earnings per share, cash flow and revenue growth and other financial results,
developments relating to our customers and end-markets, and plans concerning
business development opportunities and divestitures. Words such as "believes,"
"intends," "anticipates," "plans," "expects," "projects," "forecasts," "will"
and similar expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management's current
assumptions and expectations and no assurances can be given that our
assumptions or expectations will prove to be correct. A number of important
risk factors could cause actual results to differ materially from the results
described, implied or projected in any forward-looking statements. These
factors include, without limitation: (1) markets into which we sell our
products declining or not growing as anticipated; (2) fluctuations in the
global economic and political environments; (3) our failure to introduce new
products in a timely manner; (4) our ability to execute acquisitions and
license technologies, or to successfully integrate acquired businesses and
licensed technologies into our existing business or to make them profitable,
or successfully divest businesses; (5) our failure to adequately protect our
intellectual property; (6) the loss of any of our licenses or licensed rights;
(7) our ability to compete effectively; (8) fluctuation in our quarterly
operating results and our ability to adjust our operations to address
unexpected changes; (9) significant disruption in third-party package delivery
and import/export services or significant increases in prices for those
services; (10) disruptions in the supply of raw materials and supplies; (11)
the manufacture and sale of products exposing us to product liability claims;
(12) our failure to maintain compliance with applicable government
regulations; (13) regulatory changes; (14) our failure to comply with
healthcare industry regulations; (15) economic, political and other risks
associated with foreign operations; (16) our ability to retain key personnel;
(17) significant disruption in our information technology systems; (18) our
ability to obtain future financing; (19) restrictions in our credit
agreements; (20) our ability to realize the full value of our intangible
assets; (21) significant fluctuations in our stock price; (22) reduction or
elimination of dividends on our common stock; and (23) other factors which we
describe under the caption "Risk Factors" in our most recent quarterly report
on Form 10-Q and in our other filings with the Securities and Exchange
Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after the
date of this press release.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The company reported revenue of
approximately $1.9 billion in 2011, has about 7,400 employees serving
customers in more than 150 countries, and is a component of the S&P 500 Index.
Additional information is available through 1-877-PKI-NYSE, or at
www.perkinelmer.com.

About the verifi^® prenatal test

The verifi^® prenatal test is a blood test that analyzes genetic material (or
DNA) naturally found in a pregnant woman’s blood to detect the most common
fetal chromosome abnormalities. When directed by a physician, the verifi^®
test can be offered to pregnant women of at least 10 weeks gestation at high
risk of carrying a fetus with a genetic abnormality. For more information on
the verifi^® test, please contact Verinata Health’s Client Services at
1-855-266-6563 (BMOMKND).

About Verinata Health

Verinata Health, Inc. is driven by a sole, extraordinary purpose – maternal
and fetal health. Our initial focus is to develop and offer non-invasive tests
for early identification of fetal chromosomal abnormalities using our
proprietary technologies. We aim to reduce the anxiety associated with today’s
multi-step process, the unacceptable false-positive rates, the non-specific
and sometimes confusing results of current prenatal screening methods, as well
as the risk of current invasive procedures. We support national guidelines and
the recent American College of Obstetricians and Gynecologists and the Society
for Maternal-Fetal Medicine Committee Opinion recommending cell-free DNA
prenatal testing is one option that can be used as a primary or secondary
screening test in women at increased risk of aneuploidy. We believe women who
desire such testing should be offered a single blood draw test with a
definitive result. The verifi^® prenatal test is available in the United
States through a physician. For more information about Verinata, please go to
www.verinata.com

Contact:

Investor Relations:
PerkinElmer, Inc.
Tommy Thomas, 781-663-5889
tommy.thomas@perkinelmer.com
or
Media Contacts:
Edelman (On behalf of PerkinElmer, Inc.)
Paul Barren, 404-460-9679
paul.barren@edelman.com
or
PerkinElmer, Inc.
Stephanie R. Wasco, 781-663-5701
stephanie.wasco@perkinelmer.com
or
Verinata Health, Inc.
Angela Bitting, 925-202-6211
abitting@verinata.com
or
Brewlife (On behalf of Verinata)
Denise Powell, 510-703-9491
dpowell@brewlife.com
 
Press spacebar to pause and continue. Press esc to stop.